The present invention relates to novel oligonucleotides which comprise p53 5′-UTR sequence TCCCTGG (SEQ ID NO: 1) or the complementary p53 3′-UTR sequence CCAGGGA (SEQ ID NO: 2) and their use for such therapeutic applications as protection of normal tissues from the toxicities of chemical or radiation exposure reducing tissue damage in hypoxia-reperfusion injury, neurodegenerative disorders, oxidative stress, injuries, hyperthermia preventing aging preservation of tissues and organs prior to transplanting, etc.
